http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013106216-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-912 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 |
| filingDate | 2011-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013106216-A |
| titleOfInvention | BIOMARKERS OF CHRONIC Lymphocytic Leukemia |
| abstract | 1. A method of treating a patient with chronic lymphocytic leukemia (CLL), comprising administering to the patient a therapeutically effective amount of an anti-CLL drug if it is found that the patient has an increased amount of one or more biomarkers selected from siRNA-151 3p (miRNA151 3p) , siRNA409 3p and PTK2.2. The method of claim 1, wherein the anti-CLL drug induces FAK (focal adhesion kinase) signaling or homotypic adhesion. The method of claim 1, wherein the anti-CLL drug is a B-cell antagonist. The method of claim 1, wherein the anti-CLL drug is an anti-CD20.5 antibody. The method of claim 4, wherein the anti-CD20 antibody is a humanized, human, or chimeric anti-CD20 antibody. The method of claim 4, wherein the anti-CD20 antibody is selected from the group consisting of rituximab, ofatumumab, GA101, SBI-087, veltuzumab, and AME-133.7. The method of claim 6, wherein the anti-CD20 antibody is rituximab. The method of claim 1, wherein the patient has greater disease progression-free survival (PFS) relative to a patient who does not have an increased amount of biomarker. The method of claim 1, further comprising administering chemotherapy to the patient. The method of claim 9, wherein the chemotherapy includes cyclophosphamide and fludarabine. The method of claim 1, wherein the patient has an increased amount of siRNA151 3p.12. The method according to claim 1, where the patient has an increased amount of siRNA409 3p.13. The method of claim 1, wherein the patient has an increased amount of PTK2 (protein tyrosine kinase 2). The method of claim 1, wherein the amount of biomarker is evaluated by profiling gene expression. The method of claim 14, wherein profiling the gene expression comprises |
| priorityDate | 2010-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.